Clinical Trials · NCT04683237
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
- Phase
- Phase 2/Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- Xiaojun Chen
- Enrollment
- 0
- Start date
- Mar 2021
- Locations
- See registry
- Primary endpoint
- Pathological complete response (CR) rates